tirzepatide nejm vs Semaglutide for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% weight loss at 72 wks • Semaglutide: −13.7% • Greater waist reduction Tirzepatide for MASH with Liver

Mantsiou C, Karagiannis T, Kakotrichi P, Malandris K, Avgerinos I, Liakos A, Tsapas A, Bekiari E

Amazingly, L-glutathione is key to regulating a healthy immune response

On July 23: BPC-157, KPV, TB-500, and MOTS-c

The bacteriostatic agent extends usable life to approximately 4-6 weeks when stored properly and handled with good aseptic technique

Central 5-HTergic hyperactivity induces myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like pathophysiology

Here is what you can expect: Consultation We review your health history, weight loss goals, and determine whether this weight loss injection is appropriate for your plan